ACG Wealth’s Cellebrite CLBT Stock Holding History

ACG Wealth’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-800	Closed	-$4K	–	364
2022 Q2	$4K	Buy	+800	New	+$4.16K	﹤0.01%	770

Other funds holding CLBT

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

Isomer Partners New York $74.3M AUM 23.95% 1-Year Est. Return

Crosslink Capital Menlo Park, California $1.02B AUM 9.21% 1-Year Est. Return

CIBC Asset Management

CIBC Asset Management Toronto, Ontario, Canada $40.9B AUM 35.96% 1-Year Est. Return

Makena Capital Management Menlo Park, California $866M AUM 17.79% 1-Year Est. Return

Crescent Park Management East Palo Alto, California $29M AUM 1.79% 1-Year Est. Return

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

ACG Wealth's CLBT Position: Q3 2022 in Review

ACG Wealth sold out of Cellebrite (CLBT) in Q3 2022, closing a stake of 800 shares — an estimated $4K sold.

ACG Wealth first reported a position in CLBT in Q2 2022 and held it in 1 quarter. The position peaked at $4K in Q2 2022. 44 funds tracked by Wall St. Rank hold CLBT as of Q3 2022.

ACG Wealth reported no remaining Cellebrite position as of Q3 2022 after selling out during the quarter.
ACG Wealth sold 800 Cellebrite shares in Q3 2022, an estimated $4K.
ACG Wealth first reported a position in Cellebrite in Q2 2022 and held it in 1 quarter.
ACG Wealth's Cellebrite position peaked at $4K in Q2 2022.
44 funds tracked by Wall St. Rank held Cellebrite as of Q3 2022.

Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.